Azienda Ospedaliera S Maria Di Terni

At Azienda Ospedaliera S Maria Di Terni, clinical trials in oncology and male urogenital diseases focus heavily on urothelial cancer, bladder cancer, renal cell carcinoma, and prostate cancer. These studies are largely aimed at testing new treatment options, comparing them with current standards, and improving outcomes for people with advanced or difficult-to-treat disease.

• Advanced urothelial carcinoma and bladder cancer: evaluating new therapies and treatment combinations
• Renal cell carcinoma: studying approaches to improve survival and delay progression
• Prostate cancer: assessing better options for metastatic and castration-resistant disease

The site shows a strong emphasis on treatments for advanced solid tumors, with a clear interest in helping refine care for patients who have limited standard options.

Research in hemic and lymphatic diseases is a major part of the trial portfolio, covering multiple myeloma, chronic lymphocytic leukemia, and several forms of lymphoma. The studies are designed to compare treatment effectiveness, support longer disease control, and explore better strategies for newly diagnosed as well as relapsed or refractory blood cancers.

• Multiple myeloma: testing combinations for newly diagnosed, relapsed, and maintenance settings
• Chronic lymphocytic leukemia and small lymphocytic lymphoma: evaluating frontline and later-line treatment options
• Lymphomas including follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma: improving response and disease control

This is a particularly active area at the site, with many trials aiming to improve outcomes for patients with complex hematologic malignancies.

Another important research area at Azienda Ospedaliera S Maria Di Terni is respiratory tract diseases, especially non-small cell lung cancer and small cell lung cancer. The trials in this field are focused on testing new immunotherapy-based and targeted treatment approaches, with the goal of extending survival and improving disease control in both early and advanced stages.

• Non-small cell lung cancer: studying new combinations for untreated, advanced, and resected disease
• Small cell lung cancer: evaluating treatment approaches after initial therapy
• EGFR-mutated lung cancer: assessing targeted strategies to improve long-term outcomes

The thoracic oncology portfolio reflects a strong interest in modern precision medicine and immunotherapy for lung cancer care.

Trials in neoplasms also include a broad range of other solid tumors, with particular attention to advanced cancer and metastatic disease. Studies address breast cancer, renal tumors, and selected gynecological cancers, often aiming to improve treatment effectiveness or support better disease-free survival after standard care.

• Breast cancer: exploring targeted and endocrine-based treatment strategies
• Renal and papillary renal cancers: testing new approaches for metastatic and unresectable disease
• Advanced solid tumors: assessing therapies for difficult-to-treat tumor types across several specialties

The research profile suggests a broad commitment to improving care across multiple solid tumor types, not just one cancer category.

In addition to cancer-focused work, the site also contributes to trials in immune system diseases, nervous system diseases, cardiovascular diseases, and hormonal diseases. These studies include conditions such as myelofibrosis, Parkinson’s disease, hypertension, and treatment-related symptoms like vasomotor symptoms, showing a wider research interest beyond oncology.

• Myelofibrosis and related blood disorders: evaluating symptom control and disease management
• Parkinson’s disease and neuropathy: studying neurologic conditions with unmet needs
• Cardiovascular and hormonal conditions: exploring supportive and preventive care questions

These additional studies broaden the clinical research landscape at the hospital and highlight its role in both disease-specific and supportive care research.